Evidence map›Paper›PMID 26847534›Full record

ArticleScientific reports2016

Negative regulation of initial steps in skeletal myogenesis by mTOR and other kinases.

Raphael A Wilson, Jing Liu, Lin Xu, James Annis, Sara Helmig, Gregory Moore, Casey Timmerman, Carla Grandori, Yanbin Zheng, Stephen X Skapek

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Raphael A WilsonDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jing LiuDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Lin XuDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
James AnnisQuellos High Throughput Screening Core, Department of Pharmacology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
Sara HelmigDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Gregory MooreDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Casey TimmermanDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Carla GrandoriQuellos High Throughput Screening Core, Department of Pharmacology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
Yanbin ZhengDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Stephen X SkapekDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
The University of Texas Southwestern Medical Center · USHigh Throughput Biology (United States) · USUniversity of Washington · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
NCI NIH HHS 5P30CA142543NCI NIH HHS P30 CA142543
6 · The paper itself

Abstract

The transition from a committed progenitor cell to one that is actively differentiating represents a process that is fundamentally important in skeletal myogenesis. Although the expression and functional activation of myogenic regulatory transcription factors (MRFs) are well known to govern lineage commitment and differentiation, exactly how the first steps in differentiation are suppressed in a proliferating myoblast is much less clear. We used cultured mammalian myoblasts and an RNA interference library targeting 571 kinases to identify those that may repress muscle differentiation in proliferating myoblasts in the presence or absence of a sensitizing agent directed toward CDK4/6, a kinase previously established to impede muscle gene expression. We identified 55 kinases whose knockdown promoted myoblast differentiation, either independently or in conjunction with the sensitizer. A number of the hit kinases could be connected to known MRFs, directly or through one interaction node. Focusing on one hit, Mtor, we validated its role to impede differentiation in proliferating myoblasts and carried out mechanistic studies to show that it acts, in part, by a rapamycin-sensitive complex that involves Raptor. Our findings inform our understanding of kinases that can block the transition from lineage commitment to a differentiating state in myoblasts and offer a useful resource for others studying myogenic differentiation.

Indexed as

Muscle DevelopmentAdaptor Proteins, Signal TransducingAnimalsCell Cycle CheckpointsCell DifferentiationCell LineCell ProliferationMiceMicroscopy, FluorescenceMyoblastsMyogeninPiperazinesProtein Array AnalysisProtein KinasesPyridinesReal-Time Polymerase Chain ReactionAdaptor Proteins, Signal TransducingMyogeninpalbociclibPiperazinesProtein KinasesPyridinesRegulatory-Associated Protein of mTORRNA, MessengerRNA, Small InterferingRptor protein, mouseTOR Serine-Threonine Kinases

Identifiers

PMID26847534
PMCPMC4742887
OpenAlexW2468692415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.